You have 9 free searches left this month | to do more

carfilzomib

Carfilzomib is a drug used to treat Multiple Myeloma, Recurrent Plasma Cell Myeloma, Lymphoma, and other conditions. Carfilzomib is being actively studied in 84 studies and prior, has been studied in 52.

Top SponsorsTop SitesTop Investigators
AmgenHackensack University Medical CenterJonathan Kaufman
M.D. Anderson Cancer CenterMayo ClinicAjai Chari
National Cancer Institute (NCI)Washington University School of MedicineAjay Nooka
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
C
Terminated
  • Hodgkin Disease
  • Lymphoma, Non-hodgkin
  • New York, New York
    Columbia University Irving Medical Center - Center for Lymphoid
2021-06-28
Jun 28, 2021
L
Recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Maywood, Illinois
    Loyola University Medical Center
2021-04-23
Apr 23, 2021
i
Recruiting
  • Multiple Myeloma in Relapse
  • Carfilzomib
  • Frankfurt, Germany
    Centrum für Hämatologie und Onkologie Bethanien
2021-04-12
Apr 12, 2021
U
Completed
  • Hematologic Malignancies
  • +2 more
  • Ann Arbor, Michigan
    University of Michigan Hospital
2021-01-19
Jan 19, 2021
P
Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Poitiers, France
    CHU Poitiers
2021-11-25
Nov 25, 2021
O
Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +5 more
  • Encinitas, California
  • +6 more
2020-08-12
Aug 12, 2020
T
Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • San Francisco, California
  • +2 more
2021-07-14
Jul 14, 2021
U
Completed
  • Lymphoma, Non-Hodgkin
  • Lymphoma
  • Carfilzomib
  • +2 more
  • Davis, California
  • +2 more
2021-04-21
Apr 21, 2021
E
Recruiting
  • Transplants and Implants
  • Cincinnati, Ohio
  • +1 more
2020-06-29
Jun 29, 2020
J
Recruiting
  • Lung Transplant Rejection
  • Carfilzomib
  • Pittsburgh, Pennsylvania
    University of Pittsburgh Medical Center
2020-07-01
Jul 1, 2020
E
Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • Kiel, Germany
  • +2 more
2021-01-25
Jan 25, 2021
O
Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-10-19
Oct 19, 2021
U
Recruiting
  • Myeloma
  • Multiple Myeloma
  • Chicago, Illinois
    The University of Chicago
2021-09-15
Sep 15, 2021
S
Completed
  • Neuroendocrine Cancer
  • Carfilzomib
  • Denver, Colorado
  • +9 more
2021-06-21
Jun 21, 2021
P
Recruiting
  • Relapsed Solid Tumors
  • +3 more
  • Carfilzomib
  • +2 more
  • Phoenix, Arizona
  • +7 more
2021-07-06
Jul 6, 2021
C
Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Edmonton, Alberta, Canada
  • +8 more
2021-04-20
Apr 20, 2021
U
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Birmingham, United Kingdom
  • +12 more
2021-10-01
Oct 1, 2021
O
Recruiting
  • Myeloma
  • Carfilzomib
  • +3 more
  • Copenhagen, Denmark
  • +3 more
2021-09-15
Sep 15, 2021
H
Recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +3 more
  • Hackensack, New Jersey
    Hackensack Meridian Health - John Theurer Cancer Center
2021-04-01
Apr 1, 2021
M
Completed
  • Kidney Cancer
  • Carfilzomib
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2020-02-21
Feb 21, 2020
M
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2021-11-01
Nov 1, 2021
M
Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Basking Ridge, New Jersey
  • +5 more
2021-11-18
Nov 18, 2021
N
Active, not recruiting
  • Anemia
  • +2 more
  • Carfilzomib
  • +3 more
  • Atlanta, Georgia
  • +2 more
2021-11-24
Nov 24, 2021
N
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • New Haven, Connecticut
  • +4 more
2021-08-25
Aug 25, 2021